Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company's common stock at an exercise price per share of $18.54, which was the closing price.

Business Wire • Oct 26, 2026

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day

Arcus Biosciences NYSE: RCUS presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear cell renal cell carcinoma (RCC).

MarketBeat • Oct 21, 2026

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

PRNewsWire • Oct 21, 2026

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day option to purchase.

Business Wire • Oct 21, 2026

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriti.

Business Wire • Oct 22, 2026

Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead

Arcus Biosciences presented promising ARC-20 platform data for casdatifan across first-line, second-line, and late-line clear cell renal cell carcinoma settings. RCUS's casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks, with manageable safety profiles and broad potential across treatment lines. Valuation is rich at 22.5x trailing and 37.9x forward sales, reflecting high pipeline expectations and leaving RCUS vulnerable to clinical setbacks.

Seeking Alpha • Oct 21, 2026

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript

Seeking Alpha • Oct 20, 2026

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 20, 2026

Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced new data at an investor event in New York City from the ARC-20 platform study, which is evaluating casdatifan, an investigational next-generation HIF-2α inhibitor, alone or in combination, as a first-, second- and late-line treatment for clear c.

Business Wire • Oct 20, 2026

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City. The event will highlight new data from the ARC-20 platform study, which is evaluating casdatif.

Business Wire • Sep 22, 2026